Every Form 4 that VivoSim Labs Inc (VIVS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VIVS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VIVS filings page.
VivoSim Labs, INC. (VIVS) reported that its Chief Commercial Officer, Lialin Tony Serge, purchased 10,000 shares of common stock on 2026-08-31 at an average price of $0.2804 per share in an open-market or private transaction. Following this trade, he held 10,000 shares directly, and the filing’s Rule 10b5-1 checkbox was not marked as being under a trading plan.
VivoSim Labs director Douglas Jay Cohen received 15,000 shares of common stock in the form of restricted stock units on January 27, 2026 at a price of $0 per share. These units vest on the earlier of January 27, 2027 or the next annual stockholder meeting, with possible acceleration upon a change of control.
After this grant, Cohen directly beneficially owns 20,732 shares of common stock, and 83 shares are held indirectly by his son and 83 shares are held indirectly by his daughter. All share amounts reflect a 1-for-12 reverse stock split effective March 20, 2025.
VivoSim Labs executive chairman Murphy Keith received 15,000 shares of common stock as a stock-based award. The grant took place on January 27, 2026 at a price of $0.00 per share and is represented by restricted stock units.
The restricted stock units vest on the earlier of January 27, 2027 or the date of the next annual meeting of stockholders, with possible acceleration if there is a change of control. After this grant, Keith beneficially owned 26,053 shares of VivoSim Labs common stock, with all reported share amounts reflecting a prior 1-for-12 reverse stock split effective March 20, 2025.
VivoSim Labs, Inc. director Milhous Alison Tjosvold was granted 15,000 shares of common stock on January 27, 2026. The award is represented by restricted stock units that will vest on the earlier of January 27, 2027, or the next annual stockholder meeting, with potential acceleration upon a change of control. After this grant, the director beneficially owns 19,899 shares of common stock. All share amounts already reflect a 1-for-12 reverse stock split that became effective on March 20, 2025.
VivoSim Labs director David Gobel received 15,000 shares of common stock in the form of restricted stock units at no cost on January 27, 2026. These units will vest on the earlier of January 27, 2027 or the company’s next annual stockholder meeting, with potential acceleration if there is a change of control. After this award, Gobel beneficially owns 15,000 shares directly.
VivoSim Labs director Adam K. Stern received 15,000 shares of common stock on a restricted stock unit basis on January 27, 2026 at a price of $0.00 per share. These units vest on the earlier of January 27, 2027 or the next annual stockholder meeting, with possible acceleration upon a change of control. Following this award, Stern beneficially owns 19,899 shares directly. All share figures reflect a 1-for-12 reverse stock split of VivoSim Labs common stock that became effective on March 20, 2025.
VivoSim Labs, Inc. (VIVS) filed a Form 4 reporting a director’s change in ownership. On 11/17/2025, the director reported a transaction involving 3,266 shares of common stock at $2.2351 per share, and reported 0 shares beneficially owned following the transaction, held directly.
The company notes that, effective March 20, 2025, it completed a 1-for-12 reverse stock split of its common stock, and all share amounts in this filing already reflect that split.